CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo

MLA

Yuichi, Chikaraishi, et al. “CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-Alpha Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo.” Current Neurovascular Research, vol. 6, no. 3, Feb. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........7326c0e5ca50bc406d8dae2b41c2971a&authtype=sso&custid=ns315887.

APA

Yuichi, C., Masamitsu, S., Koichi, Y., Koichiro, Y., & Hideaki, H. (2009). CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. Current Neurovascular Research, 6(3).

Chicago

Yuichi, Chikaraishi, Shimazawa Masamitsu, Yokota Koichi, Yoshino Koichiro, and Hara Hideaki. 2009. “CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-Alpha Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo.” Current Neurovascular Research 6 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........7326c0e5ca50bc406d8dae2b41c2971a&authtype=sso&custid=ns315887.